Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...
Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results